Seres Therapeutics to Present SER-155 Trial Results in irEC
Event summary
- Seres Therapeutics will host a webcast on July 8, 2026, to discuss top-line results from an investigator-sponsored trial (IST) of SER-155 in immune checkpoint inhibitor-related enterocolitis (irEC).
- The IST was conducted at Memorial Sloan Kettering Cancer Center with Principal Investigator David Faleck, M.D.
- SER-155 is being evaluated for its potential to avoid immunosuppressive therapy and allow continuation of ICI cancer treatment in 15 patients with Grade 2-3 irEC.
The big picture
Seres Therapeutics is positioning SER-155 as a potential game-changer for managing irEC, a common and severe side effect of immune checkpoint inhibitor cancer therapies. With the oncology market expanding rapidly, successful outcomes from this trial could validate Seres' live biotherapeutics approach and open new avenues for treating immune-mediated adverse events without compromising cancer treatment.
What we're watching
- Clinical Efficacy
- How SER-155's immunosuppressive-free clinical response rate in irEC patients will impact its development trajectory.
- Regulatory Pathway
- Whether the Breakthrough Therapy and Fast Track designations for SER-155 will accelerate approval processes for additional indications.
- Market Positioning
- The pace at which Seres can differentiate itself in the growing oncology market with its live biotherapeutics platform.
Related topics